PharmaVentures advises Wellmarker Bio on their Clinical Trial Collaboration with MSD to evaluate WM-A1-3389 in combination with KEYTRUDA® (pembrolizumab)

PharmaVentures advises Wellmarker Bio on their Clinical Trial Collaboration with MSD to evaluate WM-A1-3389 in combination with KEYTRUDA® (pembrolizumab)

London based deal experts are the exclusive advisors for this and the ongoing partnering efforts for WM-A1-3389.

London, UK, 08 February 2023

PharmaVentures is pleased to announce that it acted as exclusive advisor for Wellmarker Bio Co., Ltd (WMBIO) on its collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) to evaluate WM-A1-3389 in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy.

Adrian Dawkes, Managing Director at PharmaVentures, said “We are pleased to have assisted WMBIO in establishing this collaboration with MSD. We have been working with Wellmarker Bio for some time now and it is gratifying to see this collaboration come to fruition. We look forward to helping Wellmarker with more partnerships as their pipeline progresses.”

Dong-Hoon Jin, CEO of Wellmarker Bio, said “This clinical trial collaboration with MSD holds great significance for WMBIO as it allows us to evaluate a first-in-class drug with a novel mechanism in combination with KEYTRUDA. We engaged PharmaVentures as our advisors for this collaboration and continue to work with them in partnering for WM-A1-3389.”

Fintan Walton, Founder and CEO of PharmaVentures, said “We are delighted to be supporting our client WMBIO in their collaboration with MSD. PharmaVentures has an extensive industry network and the specialist expertise to connect the Korean and Western Biopharma industries and vice versa, enabling them to collaborate through licensing and M&A deals.”

 KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

For press enquiries, please contact:

Lisa Holloway

Senior Marketing Manager

PharmaVentures Ltd

enquiries@pharmaventures.com

+44 (0) 1865 332700

PharmaVentures advises IntoCell on Development and License Option Agreement with ADC Therapeutics

PharmaVentures advises IntoCell on Development and License Option Agreement with ADC Therapeutics

PharmaVentures are advisors for this collaboration and the ongoing partnering efforts for IntoCell’s platform technologies and its lead programme, B7-H3 ADC.

London, UK, 05 January 2023

PharmaVentures is pleased to announce that it acted as exclusive advisor for IntoCell on its agreement with ADC Therapeutics.

Stephen Waterman, Managing Director at PharmaVentures, said “We are pleased to have assisted IntoCell with this agreement, in addition to multiple research collaborations and MTAs previously executed, and we look forward to seeing the results of combining IntoCell’s linker-payload with ADC’s antibodies.”

Tae Kyo Park, Founder and CEO of IntoCell, said “We are pleased to be collaborating with ADC Therapeutics, one of the leading companies in the ADC area. We hope to leverage ADC Therapeutics’ experience with the development and commercialisation of its own ADC ZYNLONTA®. We have been working closely with PharmaVentures for the last few years, during which time PharmaVentures has been supporting our partnering efforts for our OHPAS and PMT platform technologies and our B7-H3 ADC.”

Fintan Walton, Founder and CEO of PharmaVentures, said “We are delighted to be supporting our client IntoCell with partnering advice. IntoCell is a great example of the emerging highly innovative Korean biotech sector. This latest deal highlights PharmaVentures’ success in helping Korean and Western Biopharma companies in forming alliances.”

For press enquiries, please contact:

Lisa Holloway

Senior Marketing Manager

PharmaVentures Ltd

enquiries@pharmaventures.com

+44 (0) 1865 332700

PharmaVentures advises Lausanne Hospital (CHUV) and EPFL on their collaboration and founding of Aerium Therapeutics to develop their highly potent SARS-CoV-2 antibodies

PharmaVentures advises Lausanne Hospital (CHUV) and EPFL on their collaboration and founding of Aerium Therapeutics to develop their highly potent SARS-CoV-2 antibodies

PharmaVentures acts as transaction advisor to Lausanne University Hospital (CHUV) and EPFL.

London, UK, 24 March, 2022

PharmaVentures is pleased to announce that it acted as transaction advisor to Lausanne University Hospital (CHUV) and EPFL in Switzerland on their commercial terms related to the collaboration and licensing of their highly potent SARS-CoV-2 monoclonal antibodies to the newly founded biopharmaceutical company Aerium Therapeutics, based in Boston, MA, USA and Lausanne, Switzerland.

Fintan Walton, Founder and CEO of PharmaVentures, said “We are delighted to have advised CHUV and EPFL on their commercial terms for this break-through research that has significant potential to protect those who are left as most vulnerable to COVID-19.”

Dr. Giuseppe Pantaleo, Professor of Medicine at the CHUV, Head of Immunology and Allergy Division said “Our collaboration with Aerium Therapeutics will be key in delivering these antibodies to the clinical stage, where they have the potential to play an important role in the control and the prevention of COVID-19, particularly in all those who are not protected by vaccination.”

For press enquiries, please contact:

Lisa Holloway

Senior Marketing Manager

PharmaVentures Ltd

enquiries@pharmaventures.com

+44 (0) 1865 332700

PharmaVentures advises IntoCell on its Research Collaboration with Ab Studio

PharmaVentures advises IntoCell on its Research Collaboration with Ab Studio

PharmaVentures is pleased to announce that it acted as the lead advisor to IntoCell on its new research collaboration with Ab Studio.

Oxford, UK, 15 October 2021

PharmaVentures is pleased to announce that it acted as the lead advisor to IntoCell on its new research collaboration with Ab Studio.

This follows the recent announcement that IntoCell has established a research collaboration partnership with Ab Studio to develop antibody drug conjugate (ADC) using IntoCell’s proprietary PMT payloads and Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) linker technology, and a novel internalizing antibody from Ab Studio.

Steve Waterman, Managing Director at PharmaVentures, said “We are pleased to have assisted IntoCell with forming another research and development collaboration, and we look forward to seeing the results of combining IntoCell’s OHPAS linker and PMT payload technologies with Ab Studio’s innovative approach to antibody discovery.”

Fintan Walton, Founder and CEO of PharmaVentures, said “PharmaVentures has advised and supported IntoCell through the course of their discussion with Ab Studio for the research collaboration agreement. PharmaVentures hopes to continue the strong relationship with IntoCell in advising on their business development and licensing activities with our special insight accumulated over many years of supporting Korean biotech companies.”

 

For press enquiries, please contact:

Stephen Waterman

Managing Director

PharmaVentures Ltd

stephen@pharmaventures.com

+44 (0) 1865 332700

PharmaVentures acts as advisor to IntoCell on their ongoing collaboration agreement with Cellectar

PharmaVentures acts as advisor to Intocell on their ongoing collaboration agreement with Cellectar

PharmaVentures is pleased to announce that it is acting as advisor to Intocell on their ongoing collaboration agreement with Cellectar.

Oxford, UK, 15 July 2021

PharmaVentures is pleased to announce that it is acting as advisor to Intocell on their ongoing collaboration agreement with Cellectar.

This follows the announcement that Cellectar and Intocell have expanded their collaboration using Intocell’s proprietary OHPAS linker and payload technologies to develop novel phospholipid ether drug conjugates (PDCs).

Steve Waterman, Managing Director at PharmaVentures, said “The collaboration with Cellectar has produced exciting preclinical results with multiple payloads, and the decision to advance these programmes into Investigational New Drug (IND) enabling studies is very encouraging.

We are looking forward to continuing to support Intocell with partnering of its Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) linker and its novel payloads that promise a wider therapeutic index over existing technology. Equally exciting is the progress with its pipeline of proprietary antibody drug conjugates (ADCs), the most advanced of which is its B7-H3 ADC. ”

Fintan Walton, Founder and CEO of PharmaVentures, said “PharmaVentures is pleased to have advised Intocell throughout the initiation, negotiation, and execution of this multi-target collaboration agreement with Cellectar. PharmaVentures has a long and strong history in supporting our clients in their deal making activities due to our considerable transactional insight of the healthcare sector.  Furthermore, our specialist knowledge and experience of the Korean emerging biopharmaceutical sector sets us apart from other transactions advisory firms.”

 

For press enquiries, please contact:

Lisa Holloway

Senior Marketing Manager

PharmaVentures Ltd

enquiries@pharmaventures.com

+44 (0) 1865 332700